Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplinalkib in ALK/ROS1+ Advanced Solid Tumors
NCT03389815Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iruplinalkib in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
iruplinalkib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03389815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389815.